Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b/4 Open-label Study of mRNA-1283.251 COVID-19 Variant-containing Vaccine Formulations
2025-000561-85Phase 3
- Sponsor
- Moderna Inc
- Start
- Mar 2026
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of mNEXSPIKE in coronavirus disease 2019 (COVID-19), sponsored by Moderna Inc. Primary endpoint: Neutralizing antibody geometric mean against vaccine-matched COVID-19 variants.
02
Drugs
mNEXSPIKE
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2025-000561-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-000561-85.